Skip to main content

Table 2 IHC features of PsA and Abneg RA cohorts based on the achievement of MDA and DAS remission after 6 months follow-up

From: Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis

  PsA cohort
Naive (N = 12) p MTX-IR (N = 22) p 1
MDA (N = 6) No MDA (N = 6) MDA (N = 9) No MDA (N = 13)
Follicular synovitis, n (%) 3 (50.0) 3 (50.0) 1.00 3 (33.3) 7 (53.8) 0.34
CD68 (L) (mean ± SD) 1.58 ± 0.80 2.42 ± 0.73 0.09 1.86 ± 0.90 2.0 ± 1.07 0.77
CD68 (SL) (mean ± SD) 1.25 ± 1.08 2.16 ± 0.61 0.13 1.77 ± 0.93 2.0 ± 1.07 0.54
CD21 (mean ± SD) 0.58 ± 0.92 0.92 ± 1.02 0.59 0.96 ± 0.80 0.33 ± 0.43 0.06
CD20 (mean ± SD) 0.83 ± 0.82 1.17 ± 0.93 0.56 1.19 ± 0.83 1.06 ± 0.40 0.64
CD3 (mean ± SD) 0.91 ± 0.33 1.99 ± 0.84 0.02 1.65 ± 0.77 2.11 ± 0.96 0.29
CD117 (mean ± SD) 1.16 ± 0.82 1.42 ± 0.49 0.62 1.12 ± 0.62 1.39 ± 0.61 0.32
CD138 (mean ± SD) 0.67 ± 0.75 1.25 ± 0.88 0.25 0.58 ± 0.64 0.61 ± 0.60 0.84
CD31+ vessels (mean ± SD) 32.50 ± 13.41 40.75 ± 6.84 0.39 22.81 ± 11.31 25.21 ± 13.06 0.58
  Abneg RA cohort
Naive (N = 27) p 2 MTX-IR (N = 28) p 3
REM (N = 11) No REM (N = 16) REM (N = 11) No REM (N = 17)
Follicular synovitis, n (%) 6 (46.2) 6 (42.6) 0.86 3 (27.3) 7 (41.2) 0.45
CD68 (L) (mean ± SD) 1.86 ± 0.82 2.23 ± 0.68 0.27 2.10 ± 0.51 1.97 ± 0.83 0.82
CD68 (SL) (mean ± SD) 0.92 ± 0.58 2.13 ± 0.55 < 0.001 1.35 ± 0.78 1.46 ± 0.76 0.66
CD21 (mean ± SD) 0.39 ± 0.74 0.65 ± 1.08 0.79 0.54 ± 0.79 0.77 ± 1.13 0.78
CD20 (mean ± SD) 1.64 ± 1.02 1.23 ± 0.78 0.26 1.46 ± 0.99 1.44 ± 0.83 0.85
CD3 (mean ± SD) 1.57 ± 0.95 1.57 ± 0.83 0.98 1.59 ± 0.89 1.47 ± 0.87 0.49
CD117 (mean ± SD) 0.57 ± 0.43 0.62 ± 0.46 0.79 0.77 ± 0.56 0.56 ± 0.43 0.28
CD138 (mean ± SD) 1.54 ± 0.99 1.77 ± 1.05 0.55 1.36 ± 1.07 1.62 ± 1.28 0.47
CD31+ vessels (mean ± SD) 35.64 ± 7.69 34.64 ± 6.89 0.54 22.35 ± 5.28 21.88 ± 5.78 0.52
  1. Data presented in italics have p < 0.05
  2. PsA psoriatic arthritis, Ab autoantibody, RA rheumatoid arthritis, MDA Minimal Disease Activity, REM remission, DAS Disease Activity Score, p naive PsA reaching MDA vs naive PsA not achieving MDA, p1 MTX-IR PsA reaching MDA vs MTX-IR PsA not achieving MDA, p2 naive ABneg RA reaching DAS remission vs naive ABneg RA not achieving DAS remission, p3 MTX-IR ABneg RA reaching DAS remission vs MTX-IR ABneg RA not achieving DAS remission, MTX-IR methotrexate inadequately responder